Lexicon and Bristol-Myers Squibb select development candidate for neuropathic pain

Lexicon Pharmaceuticals, a biopharmaceutical company focused on developing breakthrough treatments for human disease, has announced that they have selected a development candidate for neuropathic pain as part of their neuroscience drug discovery and development alliance with Bristol-Myers Squibb. 

Lexicon and Bristol-Myers Squibb are proceeding with plans to progress the development candidate through Investigational New Drug (IND) enabling studies in preparation for the commencement of clinical trials. 

New drug candidate marks the culmination of a long-standing collaboration between Lexicon and Bristol-Myers

Bristol-Myers Squibb has the first option under the alliance to obtain exclusive clinical development and commercialisation rights upon the initiation of Phase 1 clinical studies, subject to the payment of milestones and royalties to Lexicon.

“The selection of this very promising drug candidate for neuropathic pain marks the culmination of a long-standing and highly-productive collaborative effort between Lexicon and Bristol-Myers Squibb,” said Lonnel Coats, Lexicon’s president and chief executive officer.  “We look forward to bringing innovation from this novel mechanism to patients in an area of high unmet need.”

Lexicon and Bristol-Myers Squibb established a drug discovery alliance in December 2003 to discover, develop and commercialise small molecule drugs in the neuroscience field. 

For more information about Lexicon, please visit www.lexpharma.com.